← All market reports

Immunology & Biologics Market Research Reports 2026

Immunology & Biologics strategy requires evidence that connects regulatory context with practical adoption behavior in each market.

Immunology has matured from anti‑TNF monopolies into stratified cytokine inhibition and targeted synthetic small molecules spanning rheumatology, dermatology, and gastroenterology. Adalimumab biosimilars fractured originator fortress economics while originators defend with citrate‑free syringes and wearables adherence programmes. IL‑17secukinumab class plus IL‑23 guselkumab rivalry define psoriatic arthritis and axial spondyloarthritis share battles. Jak inhibitors (upadacitinib, tofacitinib, filgotinib where approved) diversify oral alternatives but amplify boxed warnings discussions around thromboembolism vigilance influencing Gulf insurer medical policy overlays. GI biologics (infliximab, vedolizumab, ustekinumab; emerging IL‑23 Risankizumab) tie infusion centre occupancy to IBD phenotype severity migration from infectious mimics endemic in traveller populations.

Explore all market reports or compare market-level rollout constraints in the GCC country report hub. Current coverage includes GCC, Saudi Arabia, United Arab Emirates, Kuwait, and 10 other markets.